Lindbrook Capital’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | $53.4K | Buy |
483
+110
| +29% | +$12.2K | ﹤0.01% | 974 |
|
|
2024
Q4 | $50.9K | Buy |
373
+130
| +53% | +$17.7K | ﹤0.01% | 805 |
|
|
2024
Q3 | $28K | Buy |
243
+17
| +8% | +$1.96K | ﹤0.01% | 1105 |
|
|
2024
Q2 | $31.1K | Buy |
226
+8
| +4% | +$1.1K | ﹤0.01% | 1001 |
|
|
2024
Q1 | $30.1K | Buy |
218
+9
| +4% | +$1.24K | ﹤0.01% | 1009 |
|
|
2023
Q4 | $27.5K | Buy |
209
+96
| +85% | +$12.6K | ﹤0.01% | 1013 |
|
|
2023
Q3 | $12.7K | Buy |
113
+59
| +109% | +$6.64K | ﹤0.01% | 1288 |
|
|
2023
Q2 | $5.09K | Sell |
54
-5
| -8% | -$471 | ﹤0.01% | 1795 |
|
|
2023
Q1 | $5.97K | Sell |
59
-58
| -50% | -$5.87K | ﹤0.01% | 1775 |
|
|
2022
Q4 | $14K | Buy |
117
+28
| +31% | +$3.34K | ﹤0.01% | 1260 |
|
|
2022
Q3 | $9K | Buy |
89
+39
| +78% | +$3.94K | ﹤0.01% | 1380 |
|
|
2022
Q2 | $5K | Buy |
50
+4
| +9% | +$400 | ﹤0.01% | 1550 |
|
|
2022
Q1 | $4K | Sell |
46
-42
| -48% | -$3.65K | ﹤0.01% | 1720 |
|
|
2021
Q4 | $7K | Sell |
88
-21
| -19% | -$1.67K | ﹤0.01% | 1402 |
|
|
2021
Q3 | $10K | Hold |
109
| – | – | ﹤0.01% | 995 |
|
|
2021
Q2 | $11K | Sell |
109
-9
| -8% | -$908 | ﹤0.01% | 1017 |
|
|
2021
Q1 | $11K | Hold |
118
| – | – | ﹤0.01% | 983 |
|
|
2020
Q4 | $11K | Buy |
118
+11
| +10% | +$1.03K | ﹤0.01% | 863 |
|
|
2020
Q3 | $10K | Buy |
107
+10
| +10% | +$935 | ﹤0.01% | 836 |
|
|
2020
Q2 | $12K | Sell |
97
-19
| -16% | -$2.35K | ﹤0.01% | 781 |
|
|
2020
Q1 | $10K | Buy |
116
+1
| +0.9% | +$86 | ﹤0.01% | 760 |
|
|
2019
Q4 | $12K | Hold |
115
| – | – | ﹤0.01% | 878 |
|
|
2019
Q3 | $10K | Buy |
115
+18
| +19% | +$1.57K | ﹤0.01% | 902 |
|
|
2019
Q2 | $8K | Hold |
97
| – | – | ﹤0.01% | 953 |
|
|
2019
Q1 | $8K | Hold |
97
| – | – | ﹤0.01% | 952 |
|
|
2018
Q4 | $6K | Buy |
+97
| New | +$6K | ﹤0.01% | 970 |
|